RGD Reference Report - Increased duodenal expression of miR-146a and -155 in pediatric Crohn's disease. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Increased duodenal expression of miR-146a and -155 in pediatric Crohn's disease.

Authors: Szűcs, Dániel  Béres, Nóra Judit  Rokonay, Réka  Boros, Kriszta  Borka, Katalin  Kiss, Zoltán  Arató, András  Szabó, Attila J  Vannay, Ádám  Sziksz, Erna  Bereczki, Csaba  Veres, Gábor 
Citation: Szűcs D, etal., World J Gastroenterol. 2016 Jul 14;22(26):6027-35. doi: 10.3748/wjg.v22.i26.6027.
RGD ID: 25671466
Pubmed: PMID:27468194   (View Abstract at PubMed)
PMCID: PMC4948267   (View Article at PubMed Central)
DOI: DOI:10.3748/wjg.v22.i26.6027   (Journal Full-text)


AIM: To evaluate the role of microRNA (miR)-146a, -155 and -122 in the duodenal mucosa of pediatric patients with Crohn's disease (CD) and the effect of transforming growth factor-β (TGF-β) on these miRs in duodenal epithelial and fibroblast cells.
METHODS: Formalin-fixed, paraffin-embedded biopsies derived from the macroscopically inflamed (CD inflamed: n = 10) and intact (CD intact: n = 10) duodenal mucosa of pediatric CD patients and control children (C: n = 10) were examined. Expression of miR-146a, -155 and -122 was determined by real-time polymerase-chain reaction (PCR). The expression of the above miRs was investigated in recombinant human TGF-β (1 nmol/L, 24 h) or vehicle treated small intestinal epithelial cells (CCL-241) and primary duodenal fibroblast cells derived from healthy children as well.
RESULTS: Expression of miR-146a was significantly higher in the inflamed duodenal mucosa compared to the intact duodenal mucosa of children with CD (CD inflamed: 3.21 ± 0.50 vs CD intact: 0.62 ± 0.26, P <= 0.01) and to the control group (CD inflamed: 3.21 ± 0.50 vs C: 1.00 ± 0.33, P <= 0.05). The expression of miR-155 was significantly increased in the inflamed region of the duodenum compared to the control group (CD inflamed: 4.87 ± 1.02 vs
CONTROL: 1.00 ± 0.40, P <= 0.001). The expression of miR-122 was unchanged in the inflamed or intact mucosa of CD patients compared to controls. TGF-β treatment significantly decreased the expression of miR-155 in small intestinal epithelial cells (TGF-β: 0.7 ± 0.083 vs
CONTROL: 1 ± 0.09, P <= 0.05) and also the expression of miR-146a (TGF-β: 0.67 ± 0.04 vs
CONTROL: 1 ± 0.15, P <= 0.01) and miR-155 (TGF-β: 0.72 ± 0.09 vs
CONTROL: 1 ± 0.06, P <= 0.05) in primary duodenal fibroblasts compared to corresponding vehicle treated controls. TGF-β treatment did not influence the expression of miR-122.
CONCLUSION: The elevated expression of miR-146a and -155 in the inflamed duodenal mucosa of CD patients suggests the role of these miRs in the pathomechanism of inflammatory bowel disease. Anti-inflammatory TGF-β plays an important role in the regulation of the expression of these miRs.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Pediatric Crohn's Disease  IEP 25671466miRNA:increased expression:duodenal mucosaRGD 
Pediatric Crohn's Disease  ISOMIR155 (Homo sapiens)25671466; 25671466miRNA:increased expression:duodenal mucosaRGD 

Objects Annotated

Genes (Rattus norvegicus)
Mir155  (microRNA 155)

Genes (Mus musculus)
Mir155  (microRNA 155)

Genes (Homo sapiens)
MIR155  (microRNA 155)


Additional Information